{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-22-028771","form_type":"8-K","ticker":"OVID","cik":"0001636651","company_name":"Ovid Therapeutics Inc.","filed_at":"2022-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.521174+00:00","generated_at":"2026-06-22T03:47:35.821810+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Ovid Therapeutics Q3 2022 net loss $12.0M; $137.9M cash; OV329 Phase 1 to start Q4","bullets":["Net loss of $12.0M ($0.17 per share) vs $11.4M loss in Q3 2021; R&D expense $5.2M.","Cash, cash equivalents and marketable securities totaled $137.9M as of Sept 30, 2022.","FDA cleared IND for OV329; Phase 1 trial in healthy volunteers planned for Q4 2022.","Executed additional $3.5M investment in Gensaic convertible preferred stock for gene delivery platform.","Takeda continues pivotal Phase 3 trials for soticlestat; Ovid eligible for up to $660M milestones plus royalties."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-22-028771","json":"https://secwatch.observer/filing/0001628280-22-028771.json","markdown":"https://secwatch.observer/filing/0001628280-22-028771.md","text":"https://secwatch.observer/filing/0001628280-22-028771.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1636651/000162828022028771/0001628280-22-028771-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1636651/000162828022028771/ovid-20221108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T03:47:35.821810+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9d9e9cec8f3b0621d20cab225f5a7db54fdcb306","claim":"Ovid Therapeutics Inc. reported financial results for third quarter ended September 30, 2022.","evidence_excerpt":"On November 8, 2022 , Ovid Therapeutics Inc. (the “Company”) issued a press release announcing Third Quarter 2022 Financial Results and Corporate Highlights.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1636651/000162828022028771/0001628280-22-028771-index.htm","confidence":0.8,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}